Posted on

cannabis research studies

The new DEA decision doesn’t resolve the conflict between federal and state laws, but it does offer researchers a new, federally sanctioned pipeline for more products and strains of cannabis.

Despite their efforts, scientists have encountered administrative and legal hurdles to growing pharmaceutical-grade cannabis for decades.

Shots – Health News

For Grant of UCSD, the problem with the long-standing supply of cannabis isn’t so much the quality, but the lack of different products like edibles and oils and of cannabis strains with varying concentrations of CBD and THC, the plant’s main psychoactive ingredient.

It’s a move that promises to accelerate understanding of the plant’s health effects and possible therapies for treating conditions — chronic pain, the side effects of chemotherapy, multiple sclerosis and mental illness, among many others — that are yet to be well studied.

“It is a big disconnect,” says Dr. Igor Grant, a psychiatry professor and director of the Center for Medicinal Cannabis Research at University of California, San Diego.

We are especially interested in those papers that address developing medical and commercial uses of hemp and hemp products (such as cannabidiol) or those addressing differences between hemp and psychoactive cannabis.

30 January 2020

Processing and extraction methods of medicinal cannabis: a narrative review

Prof. Mechoulam, one of the world’s pre-eminent cannabis scientists, is the Lionel Jacobson Professor of Medicinal Chemistry at Hebrew University.

Authors: Carole M. Lindsay, Wendel D. Abel, Erica E. Jones-Edwards, Paul D. Brown, Khalia K. Bernard and Tainia T. Taylor

For more information you can read the full announcement here, or read a Q&A with Prof. Mechoulam here.